Question 1

What specific treatments will I receive if I participate in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients clinical trial (NCT06700369). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the single drug Taxane compare to the combination treatment in terms of side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients clinical trial (NCT06700369). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential risks and benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients clinical trial (NCT06700369). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients clinical trial (NCT06700369). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I don't qualify for this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients clinical trial (NCT06700369). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there other treatment options available that I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients clinical trial (NCT06700369). Contact the study team or your healthcare provider for specific answers.

What this study is about